Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights
March 09, 2017 07:00 ET
|
Sunesis Pharmaceuticals Inc
Sunesis to Host Conference Call Today at 11:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial...
Sunesis to Host Conference Call on March 9th to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights
March 02, 2017 07:00 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 9, 2017 at 11:00...
Sunesis Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference
March 01, 2017 07:00 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at...
Sunesis Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference
February 06, 2017 07:00 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at...
Sunesis Pharmaceuticals Announces Clinical and Regulatory Updates to SNS-062 and Vosaroxin Programs
January 23, 2017 07:00 ET
|
Sunesis Pharmaceuticals Inc
FDA Review of Investigational New Drug Application for SNS-062 Complete; Phase 1B/2 Study in Patients with Advanced B-Cell Malignancies to Begin Dosing in the First Half of 2017 Vosaroxin Day 180...
Sunesis Pharmaceuticals Announces Presentation of Updated Results from the VALOR Trial Examining Overall Survival in Patients Age 60 Years and Older with Relapsed/Refractory AML at the ASH Annual Meeting
December 05, 2016 17:45 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of updated results from the VALOR trial examining overall...
Sunesis Pharmaceuticals Announces Presentation of Results from Completed Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK inhibitor SNS-062 at ASH Annual Meeting
December 05, 2016 07:00 ET
|
Sunesis Pharmaceuticals Inc
Program On Track to Begin Dosing in Phase 1B/2 Study of Patients with B-Cell Malignancies in the First Half of 2017 SOUTH SAN FRANCISCO, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Sunesis...
Sunesis Pharmaceuticals Announces Presentations at ASH Annual Meeting
November 03, 2016 09:25 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced an oral and a poster presentation at the 58th American Society of...
Sunesis Pharmaceuticals Reports Third Quarter 2016 Financial Results and Recent Highlights
November 03, 2016 07:00 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the third quarter ended September 30, 2016. Loss...
Sunesis to Host Conference Call on November 3rd to Discuss Third Quarter 2016 Financial Results and Recent Highlights
October 27, 2016 07:00 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it will host a conference call on Thursday, November 3, 2016 at...